Overview

At a Glance

  • CD34+ cell therapy platform yielding a multi-product development pipeline with 2 clinical programs having regenerative medicine “breakthrough” designation
  • Proprietary field-leading technology in lucrative global indications backed by a strong IP portfolio
  • Multiple potential value creating events in the next 12-24 months based on milestones across the pipeline
  • Strong balance sheet; ~$116 million in cash & investments (2/25/2021) with no debt and cash runway projected to fund operations for several years
  • Seasoned management with noteworthy domain expertise along with big pharma and emerging biotech experience

Sign up to our e-mail list to receive Caladrius announcements.

H.C. Wainwright VIRTUAL BioConnect Conference, January 11 – 14, 2021

Investor Contact


John D. Menditto
Caladrius Biosciences, Inc.
Vice President
Investor Relations & Corporate Communications
Tel: +1-908-842-0084
Email: jmenditto@caladrius.com

Stock Chart

Maximum 30 minute delay for quote.